JP2023527575A5 - - Google Patents
Info
- Publication number
- JP2023527575A5 JP2023527575A5 JP2022574098A JP2022574098A JP2023527575A5 JP 2023527575 A5 JP2023527575 A5 JP 2023527575A5 JP 2022574098 A JP2022574098 A JP 2022574098A JP 2022574098 A JP2022574098 A JP 2022574098A JP 2023527575 A5 JP2023527575 A5 JP 2023527575A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GB2008303.6 | 2020-06-02 | ||
| EPPCT/EP2020/065244 | 2020-06-02 | ||
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| US16/890,664 US11771681B2 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compounds |
| US16/890,664 | 2020-06-02 | ||
| GBGB2018950.2A GB202018950D0 (en) | 2020-12-01 | 2020-12-01 | Parenteral formulation |
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,679 | 2020-12-01 | ||
| US17/108,938 | 2020-12-01 | ||
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GB2018955.1 | 2020-12-01 | ||
| GB2018950.2 | 2020-12-01 | ||
| US17/108,679 US20220168274A1 (en) | 2020-12-01 | 2020-12-01 | Parenteral Formulation |
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| US17/208,583 | 2021-03-22 | ||
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3 | 2021-03-22 | ||
| EPPCT/EP2021/060750 | 2021-04-23 | ||
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023527575A JP2023527575A (ja) | 2023-06-29 |
| JPWO2021244831A5 JPWO2021244831A5 (https=) | 2024-04-16 |
| JP2023527575A5 true JP2023527575A5 (https=) | 2024-04-16 |
| JP7579888B2 JP7579888B2 (ja) | 2024-11-08 |
Family
ID=76329655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574098A Active JP7579888B2 (ja) | 2020-06-02 | 2021-05-13 | 治療用固形製剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP3902541B1 (https=) |
| JP (1) | JP7579888B2 (https=) |
| CN (1) | CN115996713A (https=) |
| AU (1) | AU2021284861A1 (https=) |
| CA (1) | CA3118556A1 (https=) |
| GB (1) | GB2595776B (https=) |
| IL (1) | IL298542B2 (https=) |
| WO (2) | WO2021116503A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| MX2022009528A (es) | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| CA3146880C (en) * | 2020-07-29 | 2023-07-18 | Gregory Ellis | Delivery system for ayahuasca-like substances |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| WO2022117640A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| IL308816A (en) | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| MX2024005955A (es) | 2021-11-18 | 2024-06-11 | Cybin Uk Ltd | Formulaciones inyectables e inhalables. |
| JP2024545787A (ja) * | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| US20250051279A1 (en) * | 2022-01-14 | 2025-02-13 | Cybin Irl Limited | Tryptamine compositions and methods |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023242469A1 (en) * | 2022-03-31 | 2024-09-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| EP4522167A1 (en) | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) * | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
-
2021
- 2021-04-23 EP EP21720509.5A patent/EP3902541B1/en active Active
- 2021-04-23 WO PCT/EP2021/060750 patent/WO2021116503A2/en not_active Ceased
- 2021-05-13 WO PCT/EP2021/062794 patent/WO2021244831A1/en not_active Ceased
- 2021-05-13 AU AU2021284861A patent/AU2021284861A1/en active Pending
- 2021-05-13 CN CN202180046533.1A patent/CN115996713A/zh active Pending
- 2021-05-13 EP EP21725377.2A patent/EP4149460B8/en active Active
- 2021-05-13 CA CA3118556A patent/CA3118556A1/en active Pending
- 2021-05-13 EP EP24215587.7A patent/EP4494703A3/en active Pending
- 2021-05-13 GB GB2106881.2A patent/GB2595776B/en active Active
- 2021-05-13 IL IL298542A patent/IL298542B2/en unknown
- 2021-05-13 JP JP2022574098A patent/JP7579888B2/ja active Active